TeamDrive
RUS
Victor Stankevich

Victor Stankevich

Founding Partner, CEO

Телефоны:

+7 495 545-39-12

Send message

Viktor Stankevich is a Founding Partner of RMI Partners, a venture capital investment company in the area of innovative biopharmaceutical products.

Viktor has extensive experience of establishing and developing major projects in different sectors of the economy. In 2006-2012 Victor held different management positions at Mobile TeleSystems (MTS), one of Russia’s largest telecommunications companies. At MTS Group he was Director of External Resource Management and Control, and in 2010 was appointed Head of Procurement and a member of the Management Board.

Previously Victor spent more than 10 years (1996-2006) developing ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding. Victor was promoted from Head of Treasury to Deputy CEO. His “portfolio” of professional experience includes participation in the foundation of the Institute of Design Automation of the USSR Academy of Sciences, where he was in charge of the laboratory of artificial intelligence systems in design automation.

Victor graduated from Moscow Aviation Institute as a radio engineer, and from the Russian Foreign Trade Academy, specialising in international economic relations. Victor acquired an additional degree in 2002 from the Financial University under the Government of the Russian Federation, specialising in economics and finance.

Media Center

  • 23 November 2017

    Registration of medicines in EAEU will be performed online

    The Eurasian Economic Union (EAEU) is completing the development of a unified information system that will facilitate the registration of medicinal products by businesses in the common market and provide complete information about these drugs to consumers.

  • 23 November 2017

    Kaluga Pharmaceutical Cluster received silver certificate of Cluster Excellence

    In the period of October 24 – 26, 2017, the Association of Kaluga Pharmaceutical Cluster passed the procedure of the on-site audit conducted by the experts of the European Secretariat for Cluster Analysis. The procedure included the evaluation of the cluster management system and core activities  using 30 indicators in accordance with the methodology of the European Cluster Excellence Initiative. The assessment score of the Association of Kaluga Pharmaceutical Cluster performance for more than 70% of these indicators have significantly exceeded the required values. 

  • 22 November 2017

    After unexpected tie, Amsterdam wins ‘coin toss’ for new EMA HQ

    Well, that was unexpected. The EU’s third and final vote on the new location of the European Medicine Agency tied between Milan and Amsterdam, with Amsterdam winning the proverbial coin toss tie-breaker (EU officials drew the city’s name out of a bowl).

  • 22 November 2017

    With only 2 warnings in 2017, pharma's ad police hits historic low

    As the end of the year nears, the pharma industry can usually look back at FDA enforcement letters for insight into the agency's thinking and guidance on marketing communications. But this year, there’s not much to review.

Read more